CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
ChAdOx1.HIVconsv62 +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05604209
NCT05604209Phase 1Completed
CompareCT.gov

IGHID 12107 - A Phase I Study to Evaluate the Safety and Immunogenicity of the ChAdOx1.HIVconsv62 - MVA.tHIVconsv4 (C62-M4) or, ChAdOx1.tHIVconsv1+C62 - MVA.tHIVconsv3+M4 (C1C62-M3M4) Prime-Boost Regimens in Persons With HIV-1 Suppressed on Antiretroviral Therapy

University of North Carolina, Chapel Hill·interventional·Posted Nov 3, 2022·Updated Aug 24, 2025

In Brief

A Phase 1 clinical trial evaluating ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, and 3 other interventions for HIV Vaccine and HIV-1-infection. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

This is a double blind, randomized, placebo-controlled, parallel design study in which 18 in participants with HIV (PWH) on suppressive antiretroviral therapy will be randomly assigned to receive vaccination with C62 followed by M4 (C62-M4), C62 and C1 followed by M4 and M3 (C1C62-M3M4), or placebo. The purpose of this study is to find out: * If it is safe for people to receive intramuscular (IM) vaccination with C62-M4 or C1C62-M3M4 * If giving participants these vaccine doses will improve their immune system response to help the body get rid of HIV in the cells

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Vaccine, HIV-1-infection
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedNov 3, 2022
Enrollment StartOct 13, 2022
Primary CompletionSep 12, 2024
Study CompletionJan 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.7 years ago

Interventions

ChAdOx1.HIVconsv62biological

Administered intramuscularly (IM) at Day 0

ChAdOx1.tHIVconsv1biological

Administered intramuscularly (IM) at Day 0

MVA.tHIVconsv4biological

Administered intramuscularly (IM) at Day 28

MVA.tHIVconsv3biological

Administered intramuscularly (IM) at Day 28

Placeboother

Administered at intramuscularly (IM) Day 0 and Day 28